Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor

Traditional cancer therapy and regular immunotherapy are ineffective for treating triple‐negative breast cancer (TNBC) patients. Recently, chimeric antigen receptor‐engineered natural killer cells (CAR NK) have been applied to target several hormone receptors on different cancer cells to improve the efficacy of immunotherapy. Furthermore, epidermal growth factor receptor (EGFR) is a potential therapeutic target for TNBC. Here, we demonstrated that EGFR‐specific CAR NK cells (EGFR‐CAR NK cells) could be potentially used to treat patients with TNBC exhibiting enhanced EGFR expression.

• Publication year

  2020

• Venue

  Cell Proliferation

• Publication date

  2020-06-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/cpr.12858PMID 32592435PMCID 7445407
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Over-expression of EGFR regulated by RARA contributes to 5-FU resistance in colon cancer

  2020cited by this paper
• Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor

  2020cited by this paper
• Oncogenic functions of protein kinase D2 and D3 in regulating multiple cancer‐related pathways in breast cancer

  2019cited by this paper
• Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges.

  2019cited by this paper
• Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing

  2019cited by this paper
• The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge.

  2019cited by this paper
• EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC

  2019cited by this paper
• CAR-Expressing Natural Killer Cells for Cancer Retargeting

  2019cited by this paper
• The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.

  2019cited by this paper
• Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines

  2018cited by this paper
• Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.

  2018cited by this paper
• Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells

  2018cited by this paper
• First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

  2018cited by this paper
• Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy

  2018cited by this paper
• Chimeric antigen receptor T-cell therapies for lymphoma

  2018cited by this paper
• Targeted peptide-Au cluster binds to epidermal growth factor receptor (EGFR) in both active and inactive states: a clue for cancer inhibition through dual pathways.

  2018cited by this paper
• Cell-based immunotherapy approaches for multiple myeloma

  2018cited by this paper
• Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models

  2018cited by this paper
• Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

  2018cited by this paper
• Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer

  2018cited by this paper
• Engineering Natural Killer Cells for Cancer Immunotherapy.

  2017cited by this paper
• Oncogenic Protein Kinase D3 Regulating Networks in Invasive Breast Cancer

  2017cited by this paper
• Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts

  2017cited by this paper
• Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy

  2017cited by this paper
• Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells

  2017cited by this paper
• Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment

  2016cited by this paper
• A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

  2016cited by this paper
• Driving CAR T-cells forward

  2016cited by this paper
• A perspective on anti-EGFR therapies targeting triple-negative breast cancer.

  2016cited by this paper
• Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

  2016cited by this paper
• Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor

  2016cited by this paper
• Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations

  2014cited by this paper
• Spectrum of EGFR Gene Copy Number Changes and KRAS Gene Mutation Status in Korean Triple Negative Breast Cancer Patients

  2013cited by this paper
• Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women

  2013cited by this paper
• Integrin α5β1 simultaneously controls EGFR-dependent proliferation and Akt-dependent pro-survival signaling in epidermoid carcinoma cells

  2012cited by this paper
• Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer

  2012cited by this paper
• Role of epidermal growth factor receptor in breast cancer

  2012cited by this paper
• Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.

  2012cited by this paper
• Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

  2012cited by this paper
• EGFR is involved in control of gastric cell proliferation through activation of MAPK and Src signalling pathways in early‐weaned rats

  2011cited by this paper
• Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy

  2011cited by this paper
• Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles

  2011cited by this paper
• The role of EGFR inhibition in the treatment of non-small cell lung cancer.

  2009cited by this paper
• Triple negative breast cancers: clinical and prognostic implications.

  2009cited by this paper
• Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis

  2008cited by this paper
• Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers

  2008cited by this paper
• Triple-Negative Breast Cancer: Risk Factors to Potential Targets

  2008cited by this paper
• Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines

  2007cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK‐BR‐3 breast cancer cell proliferation

  2007cited by this paper
• EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

  2006cited by this paper
• Prognosis and prediction of response in breast cancer: the current role of the main biological markers

  1998cited by this paper

• Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy

  2025cites this paper
• PSCA-CAR-NK cells exert cytotoxic activity against PSCA-expressing tumor cells and are characterized by a specific chemokine profile.

  2025cites this paper
• A Concise Review of the Role of the NKG2D Receptor and Its Ligands in Cancer

  2025cites this paper
• CAR-NK cell therapy: promise and challenges in solid tumors

  2025cites this paper
• The Roles of Natural Killer Cells in Breast Cancer Pathobiology and their Regulation by Estrogens.

  2025cites this paper
• Prospects and applications of NK therapy in the treatment of gliomas (Review)

  2025cites this paper
• Rendering NK Cells Antigen-Specific for the Therapy of Solid Tumours

  2025cites this paper
• Covalent inhibition of epidermal growth factor receptor using a long-lived iridium(III)-afatinib probe.

  2024cites this paper
• Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies

  2024cites this paper
• The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances

  2024cites this paper
• An Injectable Puerarin Depot Can Potentiate Chimeric Antigen Receptor Natural Killer Cell Immunotherapy Against Targeted Solid Tumors by Reversing Tumor Immunosuppression.

  2024cites this paper
• Understanding the Interplay of CAR-NK Cells and Triple-Negative Breast Cancer: Insights from Computational Modeling

  2024influential citation
• Breakthrough of solid tumor treatment: CAR-NK immunotherapy

  2024cites this paper
• Research Progress of Nanomaterials Acting on NK Cells in Tumor Immunotherapy and Imaging

  2024cites this paper
• A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?

  2024cites this paper
• Recent advances and progress in immunotherapy of solid cancers.

  2024cites this paper
• Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review.

  2024cites this paper
• Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy

  2024cites this paper
• Engineered CAR-NK cells with tolerance to H2O2 and hypoxia can suppress postoperative relapse of triple-negative breast cancers.

  2024cites this paper
• Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy.

  2023cites this paper
• Advances in natural killer cell therapies for breast cancer

  2023cites this paper
• The application of autologous cancer immunotherapies in the age of memory-NK cells

  2023cites this paper
• Establishment of humanized mice and its application progress in cancer immunotherapy.

  2023cites this paper
• Engineered human pluripotent stem cell-derived natural killer cells with PD-L1 responsive immunological memory for enhanced immunotherapeutic efficacy.

  2023cites this paper
• Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities

  2023cites this paper
• Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells

  2023cites this paper
• Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer.

  2023cites this paper
• Breast cancer immunotherapy: a comprehensive review

  2023cites this paper
• Engineering approaches for innate immune-mediated tumor microenvironment remodeling

  2023cites this paper
• Chimeric antigen receptor‐based immunotherapy in breast cancer: Recent progress in China

  2023cites this paper
• CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects

  2023cites this paper
• Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential

  2023cites this paper
• The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer

  2023cites this paper
• Tailoring therapies to counter the divergent immune landscapes of breast cancer

  2023cites this paper
• Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.

  2022cites this paper
• Prospects of Immunotherapy for Triple-Negative Breast Cancer

  2022cites this paper
• Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress

  2022cites this paper
• Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors

  2022cites this paper
• Engineered NK Cells Against Cancer and Their Potential Applications Beyond

  2022cites this paper
• CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review

  2022cites this paper
• Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies

  2022cites this paper
• Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer

  2022cites this paper
• Recent progress in antibody-based therapeutics for triple-negative breast cancer

  2022cites this paper
• Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances

  2022cites this paper
• Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer

  2022cites this paper
• CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.

  2022cites this paper
• Harnessing natural killer cells to develop next‐generation cellular immunotherapy

  2022cites this paper
• The role of the natural killer (NK) cell modulation in breast cancer incidence and progress

  2022cites this paper
• Can EGFR be a therapeutic target in breast cancer?

  2022cites this paper
• Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling

  2022cites this paper
• Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

  2022cites this paper
• Preclinical and clinical studies of CAR-NK-cell therapies for malignancies

  2022influential citation
• Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential

  2022cites this paper
• Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy

  2022cites this paper
• Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox

  2022cites this paper
• Recent progress in cancer immunotherapy: Overview of current status and challenges.

  2022cites this paper
• CAR‐NK cells: the next wave of cellular therapy for cancer

  2021cites this paper
• The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review

  2021cites this paper
• The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance

  2021cites this paper
• NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development

  2021cites this paper
• IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors

  2021cites this paper
• New therapeutic modalities in breast cancer by targeting NK cell inhibitory and activating receptors

  2021cites this paper
• Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review

  2021cites this paper
• Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects

  2021cites this paper
• CAR-NK Cell: A New Paradigm in Tumor Immunotherapy

  2021influential citation
• CAR‐NK cell in cancer immunotherapy; A promising frontier

  2021cites this paper
• Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer

  2021cites this paper
• Tea polyphenol epigallocatechin-3-gallate inhibits cell proliferation in a patient-derived triple-negative breast cancer xenograft mouse model via inhibition of proline-dehydrogenase-induced effects

  2021cites this paper
• Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

  2020cites this paper
• Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor

  2020cites this paper